How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    a. Has all of the relevant evidence been taken into account?

  • Question on Consultation

    b. Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    c. Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    d. Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about donanemab

Marketing authorisation indication

2.1

Donanemab (Kisunla, Eli Lilly and Company) is indicated 'for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (APOE ε4) heterozygotes or non-carriers'.

Dosage in the marketing authorisation

Price

2.3

The list price of donanemab concentrate for solution for infusion is confidential until published by the Department for Health and Social Care.

2.4

The company has a commercial arrangement, which would have applied if donanemab had been recommended.

Sustainability